IMMUNOCORE HOLDINGS PLC

Immunocore shares dip 1.56% as biotech peers swing; investors weigh its 200‑day average, narrow price corridor, and dual‑market strategy for potential entry.

Immunocore rises 1.5% as its T‑cell therapy pipeline shows promise; above the 200‑day average, poised for bullish momentum and long‑term growth.